Theoretical Cost-Effectiveness of PCSK9 Inhibitors in Stroke Due to Intracranial Atherosclerosis - Quiz - MDSpire

Theoretical Cost-Effectiveness of PCSK9 Inhibitors in Stroke Due to Intracranial Atherosclerosis

  • By

  • Caroline Kellogg

  • Elena Badillo Goicoechea

  • David D. Kim

  • Shadi Yaghi

  • Seemant Chaturvedi

  • Rachel Mehendale

  • Karen Orjuela

  • Tareq Kass-Hout

  • Rami Z. Morsi

  • Jacqueline Morales

  • Eesha Singh

  • Aditya Jhaveri

  • Shyam Prabhakaran

  • Matthew M. Smith

  • James R. Brorson

  • Samiksha Golani

  • Sofia Mazuera

  • Rachael Kang

  • Ali Eltatawy

  • Jessica Pillajo

  • James E. Siegler

  • May 5, 2026

  • 0 min

Share

Original Source(s)

Theoretical Cost-Effectiveness of PCSK9 Inhibitors in Stroke Due to Intracranial Atherosclerosis

  • by Caroline Kellogg, Elena Badillo Goicoechea, David D. Kim, Shadi Yaghi, Seemant Chaturvedi, Rachel Mehendale, Karen Orjuela, Tareq Kass-Hout, Rami Z. Morsi, Jacqueline Morales, Eesha Singh, Aditya Jhaveri, Shyam Prabhakaran, Matthew M. Smith, James R. Brorson, Samiksha Golani, Sofia Mazuera, Rachael Kang, Ali Eltatawy, Jessica Pillajo, James E. Siegler

  • May 5, 2026

Related Content

Efficacy and safety of tirofiban for acute ischemic stroke without large and medium vessel occlusion: a systematic review and meta-analysis

Cardiometabolic index and modified cardiometabolic index are associated with early neurological deterioration in patients with acute ischemic stroke

Risk of UTI in kidney stone formers: a matched-cohort study over a median follow-up of 19 years